Key facts
- This page summarizes Piratip Pratumsuwan's Form 4 filing for ROCKET PHARMACEUTICALS, INC. (RCKT).
- 2 reported transactions and 2 derivative rows are listed below.
- Accepted by SEC: 05 Feb 2025, 19:47.
Piratip Pratumsuwan - 03 Feb 2025 Form 4 Insider Report for ROCKET PHARMACEUTICALS, INC. (RCKT)
- Reporting relationship
- Director
- Issuer ticker
- RCKT
- Reported as of
- 03 Feb 2025
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 05 Feb 2025, 19:47:19 UTC
- Prior SEC filing
- 05 Feb 2025
- Next SEC filing
- 18 Jul 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ Martin Wilson, as attorney-in-fact for Piratip Pratumsuwan
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Piratip Pratumsuwan filed Form 4 for ROCKET PHARMACEUTICALS, INC. (RCKT) on 05 Feb 2025.
Change
- Previous filing in this sequence was filed on 05 Feb 2025.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
RCKT
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +51,181
- Change %
- Price
- $0.000000
- Shares after
- 51,181
- Date
- 03 Feb 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 51,181
- Exercise price
- $10.56
- Footnotes
- F1
RCKT
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +22,443
- Change %
- Price
- $0.000000
- Shares after
- 22,443
- Date
- 03 Feb 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 22,443
- Exercise price
- $10.56
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
This option represents a right to purchase a total of 51,181 shares of Rocket Pharmaceutical, Inc. (the "Issuer")'s common stock, which will vest in equal monthly installments over a three-year period, such that all of the shares underlying this option will be fully vested on February 3, 2028.
Footnote F2
This option represents a right to purchase a total of 22,443 shares of the Issuer's common stock, which will fully vest on February 3, 2026.